NASDAQ:CDLXCardlytics Stock Price, Forecast & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Cardlytics.

Cardlytics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Cardlytics.

Cardlytics Inc (NASDAQ:CDLX) released its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.74) by $0.36. The business had revenue of $28.22 million for the quarter, compared to the consensus estimate of $30.84 million. Cardlytics had a negative return on equity of 26.42% and a negative net margin of 18.86%. The business's revenue for the quarter was down 42.1% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.12) EPS.
View Cardlytics' earnings history.

6 brokerages have issued 12 month price targets for Cardlytics' shares. Their forecasts range from $26.00 to $75.00. On average, they anticipate Cardlytics' share price to reach $55.17 in the next year.
View analysts' price targets for Cardlytics.

Media coverage about CDLX stock has trended extremely negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cardlytics earned a coverage optimism score of -4.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future.
View the latest news about Cardlytics.

Some companies that are related to Cardlytics include HUYA (HUYA), Legend Biotech (DADA), DouYu International (DOYU), Switch (SWCH), Medallia (MDLA), SVMK (SVMK), Pluralsight (PS), Tripadvisor (TRIP), 21Vianet Group (VNET), Sabre (SABR), Internet Initiative Japan (IIJIY), Model N (MODN), Health Catalyst (HCAT), Qutoutiao (QTT) and Eventbrite (EB).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include Alibaba Group (BABA), Trade Desk (TTD), Advanced Micro Devices (AMD), NVIDIA (NVDA), Caterpillar (CAT), Roku (ROKU), Micron Technology (MU), Netflix (NFLX), Square (SQ) and Walt Disney (DIS).

(CDLX) raised $76 million in an IPO on Friday, February 9th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Cardlytics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Frontier Capital Management Co. LLC (1.67%), Jennison Associates LLC (1.63%), Victory Capital Management Inc. (1.16%), Great Lakes Advisors LLC (0.72%), Ziegler Capital Management LLC (0.34%) and New York State Common Retirement Fund (0.30%). Company insiders that own Cardlytics stock include Aimia Inc, Andrew Christiansen, Bryce Youngren, Clifford Sosin, David Leslie Adams, David Thomas Evans, John L Jr Klinck, John V Balen, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Polaris Venture Management Co, Scott D Grimes and Tony Weisman.
View institutional ownership trends for Cardlytics.

CDLX stock was sold by a variety of institutional investors in the last quarter, including RMB Capital Management LLC, Frontier Capital Management Co. LLC, Hancock Whitney Corp, Hussman Strategic Advisors Inc., Jennison Associates LLC, and Brave Asset Management Inc.. Company insiders that have sold Cardlytics company stock in the last year include Aimia Inc, Andrew Christiansen, Bryce Youngren, David Leslie Adams, David Thomas Evans, John L Jr Klinck, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Scott D Grimes, and Tony Weisman.
View insider buying and selling activity for Cardlytics.

CDLX stock was purchased by a variety of institutional investors in the last quarter, including Great Lakes Advisors LLC, First Trust Advisors LP, Serengeti Asset Management LP, Tygh Capital Management Inc., Ziegler Capital Management LLC, Roubaix Capital LLC, Victory Capital Management Inc., and Calamos Advisors LLC. Company insiders that have bought Cardlytics stock in the last two years include Clifford Sosin, and John V Balen.
View insider buying and selling activity for Cardlytics.

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

Cardlytics has a market capitalization of $0.00 and generates $210.43 million in revenue each year. The company earns $-17,140,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

The official website for Cardlytics is www.cardlytics.com.

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected]